With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock?
The S&P 500 has taken off since the start of the year, climbing 17% so far and spurring some to wonder if a bull market is just around the corner. That has helped lift growth stocks as investors prepare their portfolios for better times.
And one particular stock to benefit is biotech CRISPR Therapeutics (NASDAQ: CRSP). The stock has advanced 24% so far this year. And this innovative company could be at the very beginning of its share performance story. In fact, the average Wall Street estimate calls for a 70% gain over the coming 12 months.
Are analysts too optimistic about this gene-editing specialist, or could this rising star really skyrocket from here? Let's find out.
Source Fool.com
